The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durvalumab and tremelimumab versus doxorubicin in previously untreated patients with advanced or metastatic soft tissue sarcoma: Patient-reported outcomes (PROs) of the randomized phase II MEDISARC study (AIO-STS-0415).
 
Viktor Grünwald
Employment - University Hospital Essen
Stock and Other Ownership Interests - AstraZeneca; Bicycle Therapeutics; Bristol-Myers Squibb; Genmab; MSD
Honoraria - Advanced Accelerator Applications/Novartis; Amgen; Apogepha; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Ipsen; Janssen-Cilag; Merck Serono; MSD Oncology; Ono Pharmaceutical; Pfizer
Consulting or Advisory Role - Bristol-Myers Squibb; Cureteq; Debiopharm Group; Eisai; Gilead Sciences; Ipsen; Janssen-Cilag; MSD Oncology; Novartis; Oncorena; PCI Biotech; Pfizer; Synthekine
Research Funding - Amgen (Inst); Bicycle Therapeutics (Inst); BMS (Inst); Gilead Sciences (Inst); Ipsen (Inst); MSD Oncology (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Ipsen; Janssen; Merck Serono; Pfizer
 
Barbara Hermes
No Relationships to Disclose
 
Armin Tuchscherer
No Relationships to Disclose
 
Sebastian Bauer
Honoraria - Deciphera; GlaxoSmithKline; Novartis; Pharmamar
Consulting or Advisory Role - ADC Therapeutics; Adcendo; Bayer; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Deciphera; Exelixis; GlaxoSmithKline; IDRX; Janssen-Cilag; Lilly; Mundipharma; Nanobiotix
Research Funding - Blueprint Medicines; Incyte (Inst); Novartis
Travel, Accommodations, Expenses - Pharmamar
 
Rainer Hamacher
No Relationships to Disclose
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Lars H Lindner
No Relationships to Disclose
 
Stefan Gröschel
No Relationships to Disclose
 
Peter Reichardt
Honoraria - Boehringer Ingelheim (Inst); Clinigen Group (Inst); Deciphera (Inst); PharmaMar (Inst)
Consulting or Advisory Role - Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
 
Stephan Richter
Stock and Other Ownership Interests - Daiichi Sankyo/UCB Japan
Honoraria - PharmaMar
Consulting or Advisory Role - Bayer Germany; Boehringer Ingelheim; Deciphera; PharmaMar
Research Funding - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Travel, Accommodations, Expenses - PharmaMar
 
Christoph Oing
No Relationships to Disclose
 
Marinela Augustin
No Relationships to Disclose
 
Martina Margrit Crysandt
No Relationships to Disclose
 
Martin Kortüm
No Relationships to Disclose
 
Bernd Kasper
Honoraria - Bayer; GlaxoSmithKline; Pharmamar-zeltia
Consulting or Advisory Role - Ayala Pharmaceuticals; Bayer; Boehringer Ingelheim; GlaxoSmithKline; SpringWorks Therapeutics
Research Funding - Ayala Pharmaceuticals (Inst); Cogent Medicine (Inst); PharmaMar (Inst); SpringWorks Therapeutics (Inst)
 
Marc Fischer
No Relationships to Disclose
 
Philipp Ivanyi
Stock and Other Ownership Interests - BB Biotech Ventures
Honoraria - AIMM Therapeutics; AstraZeneca; Bayer/Vital; Bristol-Myers Squibb; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD Oncology; Roche Pharma AG
Consulting or Advisory Role - Bayer/Vital; Bristol-Myers Squibb; ClinSol; Deciphera; Eisai; EUSA Pharma; Ipsen; Merck Serono; MSD; Pfizer
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; Merck Serono
Other Relationship - Merck Serono; Pfizer
(OPTIONAL) Uncompensated Relationships - AIO-Studien; German Cancer Society